Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
Status:
Completed
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
Among adult individuals with type 2 diabetes mellitus and at risk for heart failure with
impaired relaxation of the heart mildly reduced kidney filtration function (Type 4
cardiorenal syndrome) this trial will evaluate the quantitative impact of 38 weeks of
treatment with exenatide extended-release injections versus placebo. on a cardiac biomarker
blood test score, cardiac fibrosis seen on magnetic resonance scanning, cardiac strain
identified by ultrasonography and strain rate imaging, and a kidney urine biomarker score.